The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Open accessAbstract
Rosiglitazone is an FDA-approved oral antidiabetic agent for the treatment of type 2 diabetes. This compound improves insulin sensitivity through the activation of the nuclear receptor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma). In addition to sensitizing cells to insulin, the PPAR-gamma2 isoform appears to be critical for the regulation of osteoblast and adipocyte differentiation from common mesenchymal bone marrow progenitors. We have demonstrated previously that PPAR-gamma2 activated with rosiglitazone acts as a dominant inhibitor of osteoblastogenesis in murine bone marrow in vitro. Here, we show that in vivo, rosiglitazone administration results in significant bone loss. When rosiglitazone (20 microg/g body weight/d) was given to 6-month-old, nondiabetic C57BL/6 mice for 7 wk, a significant decrease in total body bone mineral density was observed. Analysis of bone microarchitecture, using micro-computed tomography, demonstrated a decrease in bone volume, trabecular width, and trabecular number and an increase in trabecular spacing. Histomorphometric analysis showed a decrease in bone formation rate, with a simultaneous increase in fat content in the bone marrow. Changes in bone morphology and structure were accompanied by changes in the expression of osteoblast- and adipocyte-specific marker genes; the expression of the osteoblast-specific genes Runx2/Cbfa1, Dlx5, and alpha1(I)collagen were decreased, whereas the expression of the adipocyte-specific fatty acid binding protein aP2, was increased. These in vivo data suggest that rosiglitazone therapy may pose a significant risk of adverse skeletal effects in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518
RetractedParfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80258-5 · Cited by 4,244
Bustin, S. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250169 · Cited by 3,872
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,705
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Bone Marrow Stromal Stem Cells: Nature, Biology, and Potential Applications
Bianco, P., Riminucci, M., Gronthos, S., & Robey, P. G. (2001) · STEM CELLS · doi:10.1634/stemcells.19-3-180 · Cited by 1,939
Diet-Induced Type II Diabetes in C57BL/6J Mice
Surwit, R. S., Kuhn, C. M., Cochrane, C., McCubbin, J. A., & Feinglos, M. N. (1988) · Diabetes · doi:10.2337/diab.37.9.1163 · Cited by 1,208
Cited by
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
Mechanisms of Disease: is osteoporosis the obesity of bone?
Rosen, C. J., & Bouxsein, M. L. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0070 · Cited by 956
Regulation of osteoblastogenesis and bone mass by Wnt10b
Bennett, C. N., Longo, K. A., Wright, W. S., Suva, L. J., Lane, T. F., Hankenson, K. D., & MacDougald, O. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408742102 · Cited by 881
Self-citationMoerman, E. J., Teng, K., Lipschitz, D. A., & Lecka‐Czernik, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00127.x · Cited by 833
Self-citationAge-related changes in total and regional fat distribution
Kuk, J. L., Saunders, T. J., Davidson, L. E., & Ross, R. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.06.001 · Cited by 778
“It is reported that thiazolidinediones may increase adipogenesis and decrease osteoblast formation in the bone marrow of mice (Rzonca et al., 2004) and diabetic women, but not men (Schwartz et al., 2006).”
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
“What, then, may be the mechanism responsible for the increased risk of fractures in thiazolidinedione-treated women? This is not fully understood, but both animal (17) and, more recently, human data (10,18) have demonstrated that thiazolidinedione administration is associated with a reduction in bone mineral density.”
BackgroundControl of Macrophage Activation and Function by PPARs
Chawla, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.216523 · Cited by 531
PPAR-γ regulates osteoclastogenesis in mice
Wan, Y., Chong, L.-W., & Evans, R. M. (2007) · Nature Medicine · doi:10.1038/nm1672 · Cited by 517
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
Self-citationGimble, J. M., Zvonic, S., Floyd, Z. E., Kassem, M., & Nuttall, M. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20777 · Cited by 495
Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation
James, A. W. (2013) · Scientifica · doi:10.1155/2013/684736 · Cited by 493
Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues
Thrailkill, K. M., Lumpkin, C. K., Bunn, R. C., Kemp, S. F., & Fowlkes, J. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00159.2005 · Cited by 490
Muruganandan, S., Roman, A. A., & Sinal, C. J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8429-z · Cited by 458
Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation
Ali, A. A., Weinstein, R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2646 · Cited by 401
Increased Bone Marrow Fat in Anorexia Nervosa
Bredella, M. A., Fazeli, P. K., Miller, K. K., Misra, M., Torriani, M., Thomas, B. J., Ghomi, R. H., Rosen, C. J., & Klibanski, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2532 · Cited by 386
Nuttall, M. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.002 · Cited by 370
Use of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
Regulation of osteogenic differentiation during skeletal development
Deng, Z.-L. (2008) · Frontiers in Bioscience · doi:10.2741/2819 · Cited by 343
David, V., Martin, A., Lafage-Proust, M.-H., Malaval, L., Peyroche, S., Jones, D. B., Vico, L., & Guignandon, A. (2007) · Endocrinology · doi:10.1210/en.2006-1704 · Cited by 321
Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone
Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., & Lecka-Czernik, B. (2007) · Endocrinology · doi:10.1210/en.2006-1587 · Cited by 302
Self-citationAlmeida, M., Ambrogini, E., Han, L., Manolagas, S. C., & Jilka, R. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.023572 · Cited by 275
Krings, A., Rahman, S., Huang, S., Lu, Y., Czernik, P. J., & Lecka-Czernik, B. (2012) · Bone · doi:10.1016/j.bone.2011.06.016 · Cited by 257
Self-citationBäckesjö, C.-M., Li, Y., Lindgren, U., & Haldosén, L.-A. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060415 · Cited by 256
The bone–fat interface: basic and clinical implications of marrow adiposity
Devlin, M. J., & Rosen, C. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70007-5 · Cited by 255
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Guntur, A. R., & Rosen, C. J. (2012) · Endocrine Practice · doi:10.4158/ep12141.ra · Cited by 150
The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis
Tencerova, M., & Kassem, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00127 · Cited by 149
Suva, L. J., Hartman, E., Dilley, J. D., Russell, S., Akel, N. S., Skinner, R. A., Hogue, W. R., Budde, U., Varughese, K. I., Kanaji, T., et al. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070417 · Cited by 75
Self-citationThe Functions of PPARs in Aging and Longevity
Erol, A. (2007) · PPAR Research · doi:10.1155/2007/39654 · Cited by 54
Sadie-Van Gijsen, H., Hough, F. S., & Ferris, W. F. (2013) · Bone · doi:10.1016/j.bone.2013.06.016 · Cited by 48
Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Metadata
- Authors
- Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka-Czernik, B.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2004-01-01
- Volume
- 145
- Issue
- 1
- Pages
- 401-406
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2166179667
- Cited by
- 454
- References
- 41
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.